Tofacitinib

In this article, we will discuss about Tofacitinib (Dosage). So, let’s get started.

Tofacitinib

Indications

Rheumatoid Arthritis

Tofacitinib (XELJANZ®/XELJANZ® XR) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).

• Limitations of Use: Use of Tofacitinib (XELJANZ®/XELJANZ® XR) in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

Psoriatic Arthritis

Tofacitinib (XELJANZ®/XELJANZ® XR) is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

• Limitations of Use: Use of Tofacitinib (XELJANZ®/XELJANZ® XR) in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

Ulcerative Colitis

Tofacitinib (XELJANZ®/XELJANZ® XR) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

• Limitations of Use: Use of Tofacitinib (XELJANZ®/XELJANZ® XR) in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

Dosage

Administration Instructions

Do not initiate Tofacitinib (XELJANZ®/XELJANZ® XR) if absolute lymphocyte count <500 cells/mm³, an absolute neutrophil count (ANC) <1000 cells/mm³ or hemoglobin <9 g/dL.

Recommended Dosage

Rheumatoid Arthritis

• Tofacitinib (XELJANZ®) 5 mg twice daily or XELJANZ XR 11 mg once daily.
• Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib (XELJANZ®) 5 mg once daily.

Psoriatic Arthritis (in combination with nonbiologic DMARDs)

• Tofacitinib (XELJANZ®) 5 mg twice daily or XELJANZ® XR 11 mg once daily.
• Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib (XELJANZ®) 5 mg once daily.

Ulcerative Colitis

• Tofacitinib (XELJANZ®) 10 mg twice daily for at least 8 weeks, then 5 or 10 mg twice daily. Discontinue after 16 weeks of 10 mg twice daily, if adequate therapeutic benefit is not achieved. Use the lowest effective dose to maintain response.
• Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment: half the total daily dosage recommended for patients with normal renal and hepatic function.

Warnings

Serious Infections: Avoid use of Tofacitinib (XELJANZ®/XELJANZ® XR) during an active serious infection, including localized infections.
Gastrointestinal Perforations: Use with caution in patients that may be at increased risk.
Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.
Immunizations: Live vaccines: Avoid use with Tofacitinib (XELJANZ®/XELJANZ® XR).

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.